Gossamer Bio Ties $250 Million Financing to FDA Milestones After Mixed PROSERA Result
Gossamer Bio has structured a private placement of up to $250 million with financing explicitly tranched to regulatory and commercial milestones for seralutinib in pulmonary arterial hypertension (PAH). Only $25 million closes upfront (expected…
